Literature DB >> 15334984

Treatment of cognitive dysfunction in psychiatric disorders.

Alice Medalia1, Rosa Lim.   

Abstract

Most people with severe and persistent psychiatric disorders have significant cognitive deficits. Both schizophrenia and affective disorders with psychosis are associated with problems in attention, memory, and executive functioning. These deficits are predictive of lower work status, impairments in social skills, and poorer response to psychosocial skills training. Cognitive impairment makes it difficult for individuals to benefit from focused skills interventions that they are offered. This article describes behavioral treatments available to address cognitive dysfunction in individuals with psychiatric disorders. The evidence for efficacy is reviewed and recommendations are made for ways to begin addressing cognitive impairment in mainstream psychiatric practice.

Entities:  

Mesh:

Year:  2004        PMID: 15334984     DOI: 10.1097/00131746-200401000-00003

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  10 in total

1.  Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses.

Authors:  Mario Pfammatter; Ulrich Martin Junghan; Hans Dieter Brenner
Journal:  Schizophr Bull       Date:  2006-08-11       Impact factor: 9.306

2.  Effects of modified electroconvulsive therapy on the cognitive function and blood parameters in female patients with schizophrenia.

Authors:  Yansheng Jiang; Hongxing Zhang; Zifan Wang; Ling Zhao; Luxian Lv
Journal:  Int J Clin Exp Med       Date:  2015-01-15

3.  Assessing functional performance using computer-based simulations of everyday activities.

Authors:  Sara J Czaja; David A Loewenstein; Chin Chin Lee; Shih Hua Fu; Philip D Harvey
Journal:  Schizophr Res       Date:  2016-11-30       Impact factor: 4.939

Review 4.  Cognitive remediation in schizophrenia.

Authors:  Alice Medalia; Jimmy Choi
Journal:  Neuropsychol Rev       Date:  2009-05-15       Impact factor: 7.444

5.  Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.

Authors:  Lisa M Hess; Helen Q Huang; Alexandra L Hanlon; William R Robinson; Rhonda Johnson; Setsuko K Chambers; Robert S Mannel; Larry Puls; Susan A Davidson; Michael Method; Shashikant Lele; Laura Havrilesky; Tina Nelson; David S Alberts
Journal:  Gynecol Oncol       Date:  2015-10-09       Impact factor: 5.482

6.  Cognitive training plus a comprehensive psychosocial programme (OPUS) versus the comprehensive psychosocial programme alone for patients with first-episode schizophrenia (the NEUROCOM trial): a study protocol for a centrally randomised, observer-blinded multi-centre clinical trial.

Authors:  Lone Vesterager; Torben Ø Christensen; Birthe B Olsen; Gertrud Krarup; Hysse B Forchhammer; Marianne Melau; Christian Gluud; Merete Nordentoft
Journal:  Trials       Date:  2011-02-09       Impact factor: 2.279

7.  Cognitive and neural strategies during control of the anterior cingulate cortex by fMRI neurofeedback in patients with schizophrenia.

Authors:  Julia S Cordes; Krystyna A Mathiak; Miriam Dyck; Eliza M Alawi; Tilman J Gaber; Florian D Zepf; Martin Klasen; Mikhail Zvyagintsev; Ruben C Gur; Klaus Mathiak
Journal:  Front Behav Neurosci       Date:  2015-06-25       Impact factor: 3.558

Review 8.  Developmental origins of brain disorders: roles for dopamine.

Authors:  Kelli M Money; Gregg D Stanwood
Journal:  Front Cell Neurosci       Date:  2013-12-19       Impact factor: 5.505

Review 9.  Cognitive remediation in schizophrenia: current status and future perspectives.

Authors:  Stefano Barlati; Giacomo Deste; Luca De Peri; Cassandra Ariu; Antonio Vita
Journal:  Schizophr Res Treatment       Date:  2013-12-17

10.  Emotion, working memory, and cognitive control in patients with first-onset and previously untreated minor depressive disorders.

Authors:  Mi Li; Shengfu Lu; Gang Wang; Lei Feng; Bingbing Fu; Ning Zhong
Journal:  J Int Med Res       Date:  2016-04-18       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.